A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving azathioprine

Journal of Gastrointestinal and Liver Diseases

Volumn 20, Issue 3, 2011, Pages 247-253

  Zabala Fernández, William ^a,h   Barreiro de Acosta, Manuel ^b,c   Echarri, Ana ^b,d   Carpio, Daniel ^b,e   Lorenzo, Aurelio ^b,c   Castro, Javier ^b,d   Martínez Ares, David ^b,f   Pereira, Santos ^b,f   Martin Granizo, Ignacio ^f   Corton, Marta ^g   Carracedo, Angel ^g   Barros, Francisco ^h  

^a UNIVERSIDAD DEL ZULIA   (Venezuela)

^b EIGA ^*  (Spain)

^c Instituto de Salud Carlos III   (Spain)

^d Universidad de La Coruña   (Spain)

^e Pontevedra Hospital   (Spain)

^f Xeral Cies Hospital of Vigo   (Spain)

^g UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^h CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

Azathioprine; ITPA; Pharmacogenetics; TPMT

Indexed keywords

AZATHIOPRINE; INOSINE TRIPHOSPHATE; INOSINE TRIPHOSPHATE PYROPHOSPHATASE; NUCLEOTIDE PYROPHOSPHATASE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALLELE; ALOPECIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG ERUPTION; DRUG RESPONSE; DRUG WITHDRAWAL; ENTERITIS; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PHARMACOGENETICS; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; AZATHIOPRINE; BONE MARROW; CHILD; FEMALE; GENOTYPE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; METHYLTRANSFERASES; MIDDLE AGED; PHARMACOGENETICS; PYROPHOSPHATASES; RETROSPECTIVE STUDIES;

EID: 80053525084     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Chocair PR, Duley JA, Simmonds HA, Cameron JS. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 1992;53: 1051-1056.
2. Tidd DM, Paterson AR. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 1974;34: 738-746.
3. Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with effcacy and toxicity. Gut 1996;39: 401-406.
4. Gisbert JP, Gomollon F, Cara C, et al. Thiopurine methyltransferase activity in infammatory bowel disease. A study on 7046 Spanish patients. Med Clin (Barc) 2005;125: 281-285.
5. Garat A, Cauffez C, Renault N, et al. Characterisation of novel defective thiopurine S-methyltransferase allelic variants. Biochem Pharmacol 2008;76: 404-415.
6. Lamers CB, Griffioen G, Van Hogezand RA, Veenendaal RA. Azathioprine: an update on clinical effcacy and safety in infammatory bowel disease. Scand J Gastroenterol Suppl 1999;34: 111-115.
7. Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identifcation of novel TPMT variants. Pharmacogenetics 2004;14: 407-417.
8. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002;51: 143-146.
9. Marinaki AM, Ansari A, Duley JA, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004;14: 181-187.
10. von Ahsen N, Armstrong VW, Behrens C, et al. Association of inosine triphosphatase 94C> A and thiopurine S-methyltransferase defciency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. Clin Chem 2005;51: 2282-2288.
11. Heller T, Oellerich M, Armstrong VW, von Ahsen N. Rapid detection of ITPA 94C> A and IVS2 21A> C gene mutations by real-time fuorescence PCR and in vitro demonstration of effect of ITPA IVS2 21A> C polymorphism on splicing effciency. Clin Chem 2004;50: 2182-2184.
12. Kurzawski M, Dziewanowski K, Lener A, Drozdzik M. TPMT but not ITPA gene polymorphism infuences the risk of azathioprine intolerance in renal transplant recipients. Eur J Clin Pharmacol 2009;65: 533-540.
13. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with infammatory bowel disease. Aliment Pharmacol Ther 2003;18: 395-400.
14. Lennard-Jones JE. Classifcation of infammatory bowel disease. Scand J Gastroenterol Suppl 1989;170: 2-6.
15. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infiximab in infammatory bowel disease. Gastroenterology 2006;130: 935-939.
16. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;55 Suppl 1: i16-35.
17. Lopez-Sanroman A, Bermejo F, Carrera E, Garcia-Plaza A. Effcacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis. Aliment Pharmacol Ther 2004;20: 161-166.
18. Sumi S, Marinaki AM, Arenas M, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet 2002;111: 360-367.
19. McLeod HL, Pritchard SC, Githang'a J, et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specifcity in Caucasian and Kenyan individuals. Pharmacogenetics 1999;9: 773-776.
20. Fraser AG, Orchard TR, Jewell DP. The effcacy of azathioprine for the treatment of infammatory bowel disease: a 30 year review. Gut 2002;50: 485-489.
21. Weersma RK, Peters FT, Oostenbrug LE, et al. Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. Aliment Pharmacol Ther 2004;20: 843-850.
22. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in infammatory bowel disease. J Gastroenterol Hepatol 2005;20: 1149-1157.
23. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118: 1025-1030.
24. Schutz E, Gummert J, Mohr F, Oellerich M. Azathioprine-induced myelosuppression in thiopurine methyltransferase defcient heart transplant recipient. Lancet 1993;341: 436.
25. Kader HA, Wenner WJ Jr, Telega GW, Maller ES, Baldassano RN. Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with infammatory bowel disease. J Clin Gastroenterol 2000;30: 409-413.
26. Stocco G, Martelossi S, Barabino A, et al. TPMT genotype and the use of thiopurines in paediatric infammatory bowel disease. Dig Liver Dis 2005;37: 940-945.
27. Ansari A, Arenas M, Greenfeld SM, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of infammatory bowel disease. Aliment Pharmacol Ther 2008;28: 973-983.
28. Okada Y, Nakamura K, Hiromura K, Nojima Y, Horiuchi R, Yamamoto K. Pro32Thr polymorphism of inosine triphosphate pyrophosphatase gene predicts effcacy of low-dose azathioprine for patients with systemic lupus erythematosus. Clin Pharmacol Ther 2009;85: 527-530.
29. Hawwa AF, Millership JS, Collier PS, et al. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br J Clin Pharmacol 2008;66: 517-528.
30. Stepchenkova EI, Tarakhovskaya ER, Spitler K, et al. Functional study of the P32T ITPA variant associated with drug sensitivity in humans. J Mol Biol 2009;392: 602-613.